Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123432 | PMC |
| http://dx.doi.org/10.1016/j.ad.2021.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system.
Arch Dermatol Res
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136, USA.
Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted.
View Article and Find Full Text PDFBeyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea.
Am J Clin Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Pityriasis rosea (PR) is a prevalent dermatological condition characterized by a distinctive herald patch, followed by secondary eruptions, often forming a "Christmas tree" pattern on the trunk. Despite its recognizable clinical presentation, the etiology of PR remains uncertain, with hypotheses pointing to both infectious and noninfectious origins. Human herpesviruses (HHV) 6 and 7 have been implicated, with evidence suggesting viral reactivation as a potential trigger.
View Article and Find Full Text PDFAtypical Rash as a Presentation of Pityriasis Rosea in a 23-Month-Old.
Cureus
November 2024
Pediatric Emergency Medicine, The Brooklyn Hospital Center, New York, USA.
Pityriasis rosea is a self-limiting skin disorder that can occur in pediatric patients. We report an atypical presentation of a 23-month-old male with a generalized rash similar in appearance to pityriasis rosea. We then review the literature on pityriasis rosea and its application to pediatrics.
View Article and Find Full Text PDFEvidence of "Silent" Hepatitis B Virus Infection in Psoriasis, Vitiligo, and Cases: A Pilot Study.
Indian J Dermatol
October 2024
From the Division of Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
Background: Psoriasis (PS), vitiligo (VT), and (PR) are chronic skin diseases often occurring as a consequence of exaggerated immune responses. These skin manifestations can be triggered as a result of the molecular mimicry between viral protein (s) and host protein (s), which could generate auto-antibodies. In addition, it can be hypothesised that skin diseases are manifestations of the reduced immunity that is observed in chronic hepatitis B virus (HBV)-infected individuals.
View Article and Find Full Text PDFComparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis.
J Clin Med
November 2024
Casa di Cura Villa Montallegro, 16100 Genoa, Italy.
Article Synopsis
- Pityriasis rosea (PR) is a skin condition that usually gets better on its own, often linked to reactivated human herpesviruses, causing mild rashes and itchiness.
- Traditional treatment focuses on reassuring patients to rest, but severe cases may require medication, prompting a study comparing various treatments.
- The analysis found that oral steroids and a combo with antihistamines were effective for itch relief, while acyclovir was the most effective for improving rash symptoms, making it the best option for more serious PR cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!